Trial Profile
Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Eosinophilic oesophagitis
- Focus Therapeutic Use
- Acronyms PEER
- Sponsors Shire
- 08 Mar 2023 Results (n=514) assessing the safety of an investigational formulation of budesonide (budesonide oral suspension; BOS) from six trials (SHP621-101 (no clinical trials registration number), MPI 101-01 (NCT00762073), MPI 101-06 (NCT01642212), SHP621-301 (NCT02605837), SHP621-302 (NCT02736409) and SHP621-303 (NCT03245840)), published in the Alimentary Pharmacology and Therapeutics.
- 01 Aug 2022 Results (N=37) published in the Journal of Pediatric Gastroenterology and Nutrition.
- 27 Oct 2021 Results of a pooled analysis of data from 6 trials (SHP621-101, MPI 101-01, MPI 101-06, SHP621-301, SHP621-302 and SHP621-303) assessing the long term safety of Budesonide oral suspension presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021